Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Like Humpty Dumpty, When The Establishment Says One Thing, They Mean The Opposite | Transparency, Schmanserancy! | “FDA Withholding Autopsy Results on People Who Died After Getting COVID-19 Vaccines” | Epoch Times

Show Me

Bannon’s War Room | Episode 2190 | Morning Edition Hour 2 | Recorded September 29, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2189 | Morning Edition Hour 1 | Recorded September 29, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | September 28, 2022 | Video: 26 Minutes 16 Seconds

Show Me

Bannon’s War Room | Episode 2188 | Evening Edition | Recorded September 28, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Merrick Garland Has Completely Politicized and Weaponized The Justice Department | Mike Davis | The Article III Project | Video: 3 Minutes 1 Second

Show Me

Bannon’s War Room | Episode 2187 | Morning Edition Hour 2 | Recorded September 28, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2186 | Morning Edition Hour 1 | Recorded September 28, 2022 | Video: 48 Minutes 58 Seconds

Show Me

September 27, 2022 | Nightly News Rebroadcast | Video: 28 Minutes 03 Seconds

Show Me

Italy’s Prime Minister’s Rousing Speech Defending the Primary Human Right of Self-Identity | In Doing So, She Established Herself As A Heretic To Totalitarian Minded Regimes And Individuals | Video: 4 Minutes 1 Second

Show Me

The Howls Of Despair Are Deafening |Establishment Politician, Liz Cheney, Says She’ll Campaign For Dems, Leave GOP If Trump Is 2024 Pick | New York Post

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded September 27, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded September 27, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded September 27, 2022 | Video: 48 Minutes 58 Seconds

Show Me

September 26, 2022 | Nightly News Rebroadcast | Video: 25 Minutes 58 Seconds

Show Me

Brandon Straka Who Started WalkAway Explains Leaving The Democrat Party

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded September 26, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded September 26, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded September 26, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Kamala Harris Says The Border Is Secure As Humans Are Trafficked In Crates | Video: 1 Minute 34 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded September 24, 2022 | Video: 48 Minutes 58 Seconds

Show Me

If You Want to Know How the Administrative State Handles Corruption Within Its Ranks, Look No Further Than Trump Derangement Syndrome and Russiagate | “The FBI Paid for Russian Disinformation While Punishing a Patriot” | Newsweek

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded September 24, 2022 | Video: 48 Minutes 58 Seconds

Show Me

September 23, 2022 | Nightly News Rebroadcast | Video: 28 Minutes 40 Seconds

Show Me

Government Incompetence And Corruption Is A Thing Of Beauty At Your Expense | “By Fraud, $45.6 Billion in US Pandemic Unemployment Insurance Was Stolen, Says Labor Dept. IG” | Epoch Times

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded September 23, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded September 23, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded September 23, 2022 | Video: 48 Minutes 57 Seconds

Show Me

September 22, 2022 | Nightly News Rebroadcast | Video: 27 Minutes 05 Seconds

Show Me

“COVID Is God’s Gift To The Left” | Jane Fonda Admits The Real Purpose Of COVID-19 Lockdowns And Mandates | Video: 1 Minute 20 Seconds

Show Me

September 21, 2022 | Nightly News Rebroadcast | Video: 26 Minutes 41 Seconds

Show Me

We Were Told Forced Medical Experimentation In The USA Was Stopped Long Ago | Once Again, It’s A Lie | Guinea Pig Kids | 2004 | BBC | Video: 25 Minutes 44 Seconds

Show Me

September 20, 2022 | Nightly News Rebroadcast | Video: 26 Minutes 21 Seconds

Show Me

New Vaxxed vs Unvaxxed Study | A Vaccine Study Frozen In Time | Del Bigtree

Show Me

September 19, 2022 | Nightly News Rebroadcast | Video: 27 Minutes 12 Seconds

Show Me

Bill Gates – The Non-Doctor Who Loves To Play God With Little Kids

Show Me

Those Of Us Who Have Left The Democrat Party Due To Its Corruption Wondered Where Did All The Real, Classical Liberals Go? | Patagonia Founder: ‘Earth Is Now Our Only Shareholder’ | the Defender

Show Me

If You Want To Know What The Democrat Establishment And Progressives Envision For America, Look No Further Than The Hell Hole That Is Martha’s Vineyard

Show Me

Faster Than You Can Say, “Get The Hell Out!”, Progressives Bid Adieu To Diversity And Sanctuary For Migrants Who Illegally Entered The United States

Show Me

Police Brutality By Local Officers Is No Laughing Matter | Neither Is The Divisive Racism And Demonization Of All Local Law Enforcement By The Corporate Media

Show Me